Literature DB >> 22443280

Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection.

Carmine Mancone1, Claudia Montaldo, Laura Santangelo, Cristina Di Giacomo, Viviana Costa, Laura Amicone, Giuseppe Ippolito, Leopoldo Paolo Pucillo, Tonino Alonzi, Marco Tripodi.   

Abstract

Hepatic fat export occurs by apolipoprotein B-100-containing lipoprotein production, whereas impaired production leads to liver steatosis. Hepatitis C virus (HCV) infection is associated to dysregulation of apoB-100 secretion and steatosis; however, the molecular mechanism by which HCV affects the apoB-100 secretion is not understood. Here, combining quantitative proteomics and computational biology, we propose ferritin heavy chain (Fth) as being the cellular determinant of apoB-100 production inhibition. By means of molecular analyses, we found that HCV nonstructural proteins and NS5A appear to be sufficient for inducing Fth up-regulation. Fth in turn was found to inhibit apoB-100 secretion leading to increased intracellular degradation via proteasome. Notably, intracellular Fth down-regulation by siRNA restores apoB-100 secretion. The inverse correlation between ferritin and plasma apoB-100 concentrations was also found in JFH-1 HCV cell culture systems (HCVcc) and HCV-infected patients. Finally, Fth expression was found to be required for robust HCV infection. These observations provide a further molecular explanation for the onset of liver steatosis and allow for hypothesizing on new therapeutic and antiviral strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22443280     DOI: 10.1021/pr201128s

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  10 in total

Review 1.  Chronic hepatitis C virus infection and lipoprotein metabolism.

Authors:  Yoshio Aizawa; Nobuyoshi Seki; Tomohisa Nagano; Hiroshi Abe
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 2.  Ferritins in Kidney Disease.

Authors:  Kayla McCullough; Subhashini Bolisetty
Journal:  Semin Nephrol       Date:  2020-03       Impact factor: 5.299

Review 3.  Proteomic approaches to analyzing hepatitis C virus biology.

Authors:  Florian Douam; Alexander Ploss
Journal:  Proteomics       Date:  2015-05-05       Impact factor: 3.984

4.  Data on the effects of low iron diet on serum lipid profile in HCV transgenic mouse model.

Authors:  Alice Conigliaro; Viviana Costa; Rosario Amato; Carmine Mancone
Journal:  Data Brief       Date:  2017-03-18

Review 5.  Long Non-coding RNAs in Hepatitis C Virus-Infected Cells.

Authors:  Marina Barriocanal; Puri Fortes
Journal:  Front Microbiol       Date:  2017-09-28       Impact factor: 5.640

Review 6.  Ferritin: An Inflammatory Player Keeping Iron at the Core of Pathogen-Host Interactions.

Authors:  Ana C Moreira; Gonçalo Mesquita; Maria Salomé Gomes
Journal:  Microorganisms       Date:  2020-04-18

7.  Evolution of ferritin levels in hepatitis C patients treated with antivirals.

Authors:  Ming-Ling Chang; Jing-Hong Hu; Ching-Hao Yen; Kuan-Hsing Chen; Chia-Jung Kuo; Ming-Shyan Lin; Cheng-Han Lee; Shiang-Chi Chen; Rong-Nan Chien
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

8.  Proteomic analysis of purified turkey adenovirus 3 virions.

Authors:  Pankaj Kumar; Jan van den Hurk; Lisanework E Ayalew; Amit Gaba; Suresh K Tikoo
Journal:  Vet Res       Date:  2015-07-09       Impact factor: 3.683

Review 9.  Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.

Authors:  Daniel J Felmlee; Mohamed Lamine Hafirassou; Mathieu Lefevre; Thomas F Baumert; Catherine Schuster
Journal:  Viruses       Date:  2013-05-23       Impact factor: 5.048

Review 10.  Applying proteomic technology to clinical virology.

Authors:  C Mancone; F Ciccosanti; C Montaldo; A B Perdomo; M Piacentini; T Alonzi; G M Fimia; M Tripodi
Journal:  Clin Microbiol Infect       Date:  2012-10-03       Impact factor: 8.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.